Coverage dated December 7, 2023 to December 8, 2023
U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patients
Headline from NBC Chicago
The U.S. Food and Drug Administration is expected to approve exa-cel for sickle cell disease in what would become the first marketed medicine to use CRISPR.
NBC Chicago's own description from its feed. We collect headlines and these descriptions, not full articles; read the original reporting below.
The breakthrough sickle cell treatment is the first approved therapy based on CRISPR, the gene editing tool that won its inventors the Nobel Prize in 2020.
The US Food and Drug Administration on Friday approved two gene-based treatments for sickle cell disease, including the first therapy that uses the gene-editing technique CRISPR, opening a new era of treatments for genetic conditions.
Regulators on Friday approved two gene therapies for sickle cell disease that doctors hope can cure the painful, inherited blood disorder that afflicts mostly Black people in the U.S.
The Food and Drug Administration has approved the world's first medicine employing CRISPR gene-editing technology to treat sickle cell disease, giving thousands of Americans new hope to treat the painful disease.
(CNN) — The US Food and Drug Administration on Friday approved two gene-based treatments for sickle cell disease, including the first therapy that uses the gene-editing
The U.S. Food and Drug Administration on Friday approved two gene-based treatments for sickle cell disease, including the first therapy that uses the gene-editing technique CRISPR, opening a new era
The FDA's approval of Casgevy, which uses the Nobel Prize-winning gene-editing therapy to treat patients with sicke cell disease, opens the door to many other therapies.
The treatment uses the revolutionary gene-editing tool CRISPR to permanently change DNA in the patient's blood cells. Sickle cell disease is a life-threatening illness that medical science has struggled to address.
The Food and Drug Administration approved two genetic treatments for sickle cell disease, including one that uses gene-editing. The approvals offer hope for patients and signal a new medical era.
The Food and Drug Administration is expected to approve a new gene editing therapy for sickle cell disease, its first green light for a Crispr treatment.
The U.S. Food and Drug Administration is expected to approve exa-cel for sickle cell disease in what would become the first marketed medicine to use CRISPR.
Most people with sickle cell disease who received a new gene editing treatment saw their pain resolve for at least one year, but longer follow up is needed
The CRISPR treatment enables people with sickle cell disease to make a normal form of hemoglobin. Other such treatments are being tested for cancer and heart disease.
Regulators on Friday approved two new gene therapies for sickle cell disease that doctors hope can cure the painful, inherited blood disorder that afflicts mostly Black people in the U.S.
The Food and Drug Administration Friday approved a new sickle cell disease treatment using the CRISPR genome editing technology. It's the first approved human gene editing therapy.
